Higher IOP may be marker for CVD

Article

Higher IOP may be a predictable marker of cardiovascular disease (CVD) in some individuals, according to a study from South Korea.

Higher IOP may be a predictable marker of cardiovascular disease (CVD) in some individuals, according to a study from South Korea published in the British Journal of Ophthalmology. The researchers found that higher IOP is associated with the presence of coronary artery calcium (CAC) in asymptomatic patients, regardless of the presence of usual cardiovascular risk factors.

The researchers’ cross-sectional study included 10,732 men and women without diagnoses of CVD or glaucoma. They measured CAC using cardiac computed tomography and IOP using a non-contact tonometer and automatic air puff control.

The researchers detected CAC in 13.7% in men and 4.3% of women. They found that increasing levels of right IOP were significantly associated with an increased prevalence of CAC. They adjusted for multiple factors - age, sex, tobacco use, alcohol use, physical activity, body mass index, educational level, centre, family history of CVD, use of dyslipidemia medication, diabetes, hypertension, total cholesterol level, high-density lipoprotein cholesterol and triglycerides - and found that the odds ratios for CAC score >0, comparing 2–4 quartiles of the right IOP with the lowest quartiles, were 1.32, 1.20 and 1.28, respectively. The associations were the same among the clinically relevant subgroups.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.